Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model.

The intracellular release of Dox via minicells eliminated the toxic side effects seen with systemic administration of free drug in vivo [ 26 ], resulting in highly significant and potent tumor regression, using 100-fold less Dox than that required to achieve the same anti-tumor effect using Doxil [ 26 ].

also in 132,142 other papers